On behalf of the American Society for Parenteral and Enteral Nutrition (ASPEN), a systematic review was conducted to evaluate the best available evidence regarding the validity of relevant body composition methods (eg, dual energy X-ray absorptiometry [DXA], ultrasound [US], and bioelectrical impedance analysis [BIA]) in clinical populations. The guidelines targeted adults >18 years of age with a potentially inflammatory condition or pathological end point associated with a specific disease or clinical condition. In total, 7375 studies were retrieved, and 15 DXA, 7 US, and 23 BIA studies provided applicable data. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses was used to assess the diagnostic accuracy of the test method against a "gold standard" reference. The Grading of Recommendations, Assessment, Development and Evaluation criteria were used to separate the evaluation of the body of evidence from the recommendations. Based on a limited number of studies and expert opinion, DXA is recommended for the assessment of fat mass in patients with a variety of disease states; however, the validity of DXA for lean mass assessment in any clinical population remains unknown. No recommendations can be made at this time to support the use of US or BIA in the clinical setting, as data to support its validity in any specific patient population are limited in scope or by the proprietary nature of manufacture-specific BIA regression models to procure body composition data, respectively. Directions for future research are provided. These clinical guidelines were approved by the ASPEN Board of Directors. (JPEN J Parenter Enteral Nutr. 2019;00:1-32)
inflammation on alterations in body composition, underscoring their importance during nutrition assessment. The validity of specific body composition techniques is well established in a wide array of healthy populations 2 ; however, for persons with acute or chronic illness, the validity of these methodologies is yet to be determined. Therefore, the intent of these guidelines is to provide the American Society for Parenteral and Enteral Nutrition (ASPEN) clinicians and researchers with practical, evidenced-based direction and recommendations on body composition assessment in various clinical populations.
Guideline Limitations
These ASPEN guidelines are based on general conclusions of health professionals who have examined the available literature focused on the diagnostic accuracy of the most common, clinically available methods for assessment of body composition (ie, dual energy x-ray absorptiometry [DXA] , ultrasound [US] , and bioelectrical impedance analyses [BIA] ) and made recommendations for use in patient populations. This report is intended to be practical, applied, and translatable. As such, it does not address the use of other predominantly research-based techniques (eg, magnetic resonance imaging [MRI] , neutron activation analysis) or techniques with limited accessibility (eg, air displacement plethysmography.) These tools are typically not readily available to most clinicians, are applied largely in a research setting, and require relatively sophisticated equipment. Additionally, any study that was technique oriented in nature, that is, comparing specific equipment against a gold standard or superior methodology in a healthy population, was excluded.
Definitions
Human body composition is an established yet still emerging field of science that explores the different distributions of lean mass (LM) versus adipose tissue and their impact on health. Despite advances in this field, human body composition research remains plagued by issues of nomenclature, in that specific compartments are often referred to in a multitude of ways, and these terms may not always be synonymous nor comparable. To address this, the body composition compartment being assessed/estimated (ie, molecular vs tissue levels) is referred to by technique ( Table 1 ). The terminology within Table 1 refers to the central, 5-level organization model used in body composition research, which includes atomic, molecular, cellular, tissue organ, and whole body levels. 3 
Target Population for Guidelines
The target population of these guidelines are adults (ࣙ18 years of age) with a potentially inflammatory condition or pathological end point associated with a specific disease or clinical condition such as cancer, cardiovascular disease (CVD), cardiac failure, diabetes, hepatic or renal disease, human immunodeficiency virus, or possessing a condition that requires surgical intervention. The term "clinical population" is used in support of this concept, and studies may include persons who may or may not be in a hospital or clinical setting, yet they possess a pathological state (ie, a diagnosis). These guidelines are not intended for athletes, healthy volunteers, persons with obesity (if not linked to a clinical condition such as metabolic syndrome, hypertension, etc) or for a specific life cycle (eg, infants, children, adolescents, pregnant or postpartum women, or older adults).
Target Audience
The intended target audience of these guidelines includes clinicians or researchers involved in delivering acute or outpatient clinical care and/or conducting interventions with specific clinical populations in the community setting (eg, cancer survivors, persons with HIV)-primarily dietitians, nurses, pharmacists, physicians, or researchers in relevant biomedical fields. These guidelines do not constitute medical or other professional advice and should not be taken as such. To the extent that the information published herein may be used to assist in the care of patients, this is the result of the sole professional judgment of the attending healthcare professional whose judgment is the primary component of quality medical care. The information presented in these guidelines is not a substitute for the exercise of such judgment by the healthcare professional. Circumstances in clinical settings and patient indications may require actions different from those recommended in this document, and in those cases, the judgment of the treating professional should prevail.
Methods
All ASPEN guidelines since 2011 have centered on key questions, planned data acquisition, and conflation (ie, merging) of their findings by reviewing pertinent randomized clinical trials (RCTs) and/or observational studies that addressed the focus area and relied on the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. 4 Previous guidelines employed GRADE and converged specific data points from RCTs and/or observational studies to guide their recommendations. The current guideline did not limit potential data points to specific study designs. Rather, studies evaluating the validity of the body composition methodologies in question (ie, DXA, US, and BIA) were included. To assess the validity, the diagnostic accuracy of the tool was assessed, which requires comparison of the test method against a "gold standard" reference (eg, DXA vs computed tomography [CT], respectively). Recently, McInnes et al 5 described the preferred reporting process that should be included in systematic reviews and meta-analyses of diagnostic test accuracy guidelines. These recommendations were used to guide question development and to evaluate the risk of bias and assessment of diagnostic accuracy of eligible studies. The GRADE methodology for standard language and the separation of the evaluation of the body of evidence from the statements of recommendations have been maintained in this guideline. The criteria for grading the evidence for each question was based on the McInnes et al 5 methods for diagnostic test accuracy rather than those described in GRADE for RCTs and observational studies. The task force of experts began by defining keywords used for the literature search. This was followed by development of key questions most relevant to this area of clinical practice and research and determining the database, timeframe for the literature search, target populations, and the specific outcomes to be addressed. The task force focused on the validity of body composition techniques most frequently utilized in patient populations, including DXA, BIA, and US. No study designs were excluded, provided validity end points and comparison against a "gold standard" were included. The GRADE process distinctly separated the body of evidence from the recommendation statements. This enabled incorporation of the weight of risks vs benefits that occur from adopting the recommendation. Thus, a recommendation may be "strong" despite comparatively weak published evidence if the net benefits outweigh the harms from its adoption. Recommendations based mainly on expert opinion were deemed weak. Table 2 describes the standard language and rationale for the GRADE assigned to a recommendation.
To qualify for the initial inclusion, studies that target clinical populations had to include DXA, BIA, or US and use a superior (ie, more precise) body composition modality as the comparator. For DXA, this could include comparisons to CT, MRI, or multicompartment models. For US, this could include comparisons to DXA, CT, MRI, or multicompartment models. For BIA, this could include DXA, CT, MRI, or multicompartment models. Studies using anthropometric measurements (eg, waist circumference, triceps skinfolds) were not included since these are considered surrogate measures of body composition. A standardized data abstraction form (DAF) was developed based on the GRADE approach and was modified to reflect the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methods for diagnostic accuracy tests. Articles selected for inclusion were independently reviewed by 2 task force members using the DAF. Results of the DAF were compared, differences were resolved by consensus, and a final DAF was created for each article. Based on the correlation coefficients across studies and using different devices, DXA appears to be a reasonably valid method to assess regional and total fat mass in a wide group of adult clinical patients. We recommend the use of DXA for assessing fat mass in patients with clinical conditions. No studies explored the validity of DXA for LM assessment in any clinical population; thus, its use for this compartment remains unknown Ultimately, 3 questions were developed for DXA, BIA, and US, which were reviewed and approved by ASPEN Board of Directors. These questions and recommendations are summarized in Table 3 . A rigorous MEDLINE database search was performed spanning January 2000 through October 2018 for each question using the MEDLINE portion of the techniques, as described by McKeever et al. 6 Filtering for validation studies, Medical Subject Heading (MeSH) folders for "Absorptiometry, Photon," "Ultrasonography," and "Electric Impedance" were searched to discover citations relevant to DXA, US, and BIA questions respectively. To meet the search criteria, citations in these folders had to be indexed in the MeSH folders for "Anthropometry," "Body Constitution," "Muscle Strength," or "Nutrition Assessment." They also had to be cross-referenced in MeSH folders for "Adults" and "Humans." To protect against miscataloged citations, the MEDLINE search was repeated using text-based search terms restricted to the title or abstract of the article. These were performed as follows.
For DXA citations, inclusion in the text-based search results required the title or abstract to contain at least 1 term each from Group 1 and Group 3, which were filtered for validation studies. Alternatively, they could contain at least 1 term each from Group 1 and Group 2, unfiltered for validation studies. Group 1: "DXA," "absorptiometry," "absorptiometer,"
and "DEXA scan" Group 2: "fat," "adipose," "lean," "muscle," "body composition," "height," "densitometry," and "photodensitometry" Group 3: "tomography," "CT scan," "CT-scan," "tomodensitometry," "Cine-CT," ("4-compartment,""4 compartment," "four compartment," and "fourcompartment")
For US citations, inclusion in our text-based search results required the title or abstract to contain at least 1 term from each the following 2 groups: Group 4: "Sonography," "Ultrasonography," "Ultrasound," "Ultra-sound," "ultra sound," "ultrasonic," "echography," and "echotomography" Group 5: AND ("percent body fat," "% body fat," "percent adipose tissue," "percent adiposity," "% adipose tissue," "% adiposity," "muscle volume," "muscle thickness," "skeletal mass," "muscle mass," "skeletal muscle index," "SMI," "intraabdominal fat," "intra-abdominal fat," "intraabdominal adipose," "intra-abdominal adipose," "intramuscular fat," "intra-muscular fat," "intramuscular adipose," "intramuscular adiposity," "subcutaneous fat," "subcutaneous adipose," "subcutaneous adiposity," "visceral adipose," "visceral adiposity," and "body composition"
For BIA citations, inclusion in our text-based search results required the title or abstract to contain at least 1 term from each the following 2 groups: Group 6: "BIA," "Bioimpedance," "Bioelectrical impedance," "Bioelectric impedance," "phase angle," "electric resistance," "electrical resistance," and "ohmic resistance" Group 7: "fat," "adipose," "lean," "muscle," "body composition," and "height"
Results
A total of 7375 studies were retrieved from Medline: 1361 for DXA; 2867 for US, and 3147 for BIA. Of these, 862 studies met the initial search criteria, and upon further review, 709 studies were eliminated for reasons including they were conducted in healthy populations, there were no validity data provided, only 1 body composition assessment method was used, and/or the comparator method was inferior (eg, anthropometrics). Based on the volume of studies that needed to be screened, requested, and fully read for inclusion prior to data abstraction, only 1 search engine was used. DAFs were completed on 153 initial studies. Based on the requirements of PRISMA, only studies that included correlation analyses (eg, Pearson, Spearman, Lin's, etc) were evaluated, leaving 15 DXA, 7 US, and 23 BIA studies for potential statistical analyses. After review of the abstracted data, evidence tables were generated for each question. Based on the evidence tables, an iterative process was used to develop practical recommendations for each question using the GRADE methodology, where applicable, and by consensus. The recommendations are summarized
Introduction
Clinicians face an ever-growing challenge in the general nutrition assessment of their patients, as 35%-40% of these individuals have obesity at the time of evaluation. 7 Many investigators have now demonstrated great variability in body composition, emphasizing not only the crude nature of body mass index but also the limitations of assessing simple body weight. [8] [9] [10] [11] [12] The study of human body composition is a science that looks beyond a unit of body weight, accounting for the distribution and proportion of LM vs adipose tissues with specific links to health outcomes. As such, human body composition assessment is of increasing interest to clinicians, who are now pressed to familiarize themselves with the language and application of different methods. 13 Body composition has been most extensively studied in oncology populations because of the exploitation of CT imaging completed for diagnostic and surveillance purposes. Several investigators have demonstrated that depleted LM is associated with treatment toxicity and/or decreased survival in patients with breast, 14, 15 colorectal, 16, 17 renal, [18] [19] [20] thyroid, 21 and pancreatic 22 cancers. However, the detection of abnormal body composition has broad applications to other chronic disease populations, including patients with hepatic disease, 23, 24 pulmonary disease, 25, 26 cardiac failure 27 and other cardiovascular conditions, 28 rheumatoid arthritis, 29 and renal disease, 30 among others. This rapidly expanding body of work reflects the clinical appreciation that compromised LM is no longer a condition restricted to aging or older adults.
Unfortunately, current bedside nutrition assessment techniques do not possess the requisite sensitivity and specificity to detect LM abnormalities, 31 especially in patients with obesity. 26, 32 Direct measurements of body composition are now considered fundamental for an in-depth evaluation of nutrition status. 33 Evaluating the validity of these techniques in clinical populations is fundamental to advancing this field and to elucidating how nutrition support or other nutrition interventions can influence body composition and associated outcomes.
Question 1: Is DXA a valid method of assessing body composition in various clinical populations?
Recommendation Based on correlation coefficients across studies and using different devices, DXA appears to be a reasonably valid methodology to assess regional and total fat mass (FM) in a heterogeneous group of adult patients. The use of DXA is recommended for assessment of FM in patients with a specific disease or clinical outcome. No studies were found that reported the validity of DXA for LM assessment in any patient population; thus, the value of its use for this compartment remains unknown.
Quality of the Evidence: Low GRADE Recommendation: Strong

Rationale
Fifteen studies utilizing DXA and a superior comparator method were used to provide potentially evaluable data for these guidelines. All DXA studies included in this review assessed FM (regional or total), yet based on the reported correlation coefficients, the validity of DXA to assess LM could not be determined. None of the 15 studies included sensitivity or specificity analysis. A portion of these studies included Bland-Altman analysis to reflect the quality of the data within their study; however, these cannot be used to calculate sensitivity and specificity parameters or be conflated among studies. Correlation coefficients (denoted by the letter "r") measure the strength and direction of a linear relationship between 2 variables (eg, appendicular skeletal muscle mass (SMM) (kg) from DXA vs muscle mass (kg) from CT). Correlation coefficients were categorized as very low (r = 0-0.20), low (r = 0.21-0.40), moderate (r = 0.41-0.60), high (r = 0.61-0.80), and very high (r = 0.81-1.0). Table 4 provides details regarding the studies utilizing DXA. Three studies included patient populations with diabetes mellitus; however, these studies did not provide comparable end points for joint analyses within this patient subgroup. [34] [35] [36] Ultimately, Pearson correlations between DXA and the reference methods were used in 8 studies for statistical comparisons to generate summary correlations and forest plots. Seven studies used CT to validate DXA measures of abdominal FM and/or total body FM, 34,37-42 and 2 studies used MRI to validate DXA measures for regional adiposity and total FM. 43, 44 Of these, 4 studies with heterogeneous patient populations (N = 874) were used to examine the correlation between CT-derived visceral adipose tissue (VAT) with DXA-derived abdominal adipose tissue 34, 37, 43, 44 ( Figure 1A ). Because of differences in the patient populations in these studies, the random effects model was used to assess the summary correlation and examine the heterogeneity between studies (I 2 ). The individual study correlations ranged from moderate to very strong (0.52-0.86), and the overall random effects summary correlation between the DXA measure of trunk fat/intra-abdominal fat/VAT and the CT assessment of VAT was strong (0.74, 95% confidence interval [CI] 0.52-0.86). As expected, heterogeneity between studies was very large (I 2 = 0.87) because of the different patient populations assessed.
Seven studies using patients with varying clinical diagnoses were used to examine the correlations between CT-derived or MRI-derived VAT and DXA-derived total FM [38] [39] [40] [41] [42] [43] [44] (Figure 1B) . The individual study correlations ranged from moderate to very strong (0.49-0.80), and the overall random effects summary correlation between the DXA measure of total body fat or % body fat and the CT or MRI assessment of VAT was strong (0.71, 95% CI 0.45-0.86). As expected, heterogeneity between studies was very large (I 2 = 0.98) because of the different patient populations assessed.
Five studies involving patients with CVD examining the correlations between CT-derived or MRI-derived VAT and DXA-derived total FM were conflated [38] [39] [40] 42, 43 (Figure 1C ). The individual study correlations ranged from moderate to very strong (0.49-0.87), and the summary correlation between the DXA measure of body fat and the CT or MRI assessment of VAT was strong (0.71, 95% CI 0.45-0.84). As expected, the heterogeneity between studies was very large (I 2 = 0.95) because of the different populations assessed.
Comments
DXA relies on x-ray technology and can be applied to human participants of any age because of the low radiation exposure involved. For a comprehensive review of this methodology, please refer to Heymsfield et al. 2 The use of DXA for body composition assessment is more challenging in the acute care setting and at this time would likely not procure results to directly impact clinical care, specifically nutrition support. For example, transporting a critically ill patient to the DXA machine to measure LM may not be a relevant priority in the context of his/her overall care. Furthermore, there is no evidence yet to guide the alteration of nutrition provision based on DXA findings. As a result, the lack of DXA studies conducted in the inpatient setting is not surprising. Its more direct application in the outpatient setting is intuitive, as these patients tend to be healthier, mobile, and possess fewer acute health conditions. However, some clinicians may be unaware of the fact that for patients referred for DXA imaging in the outpatient environment, only images of the femoral and/or lumbar spine region are obtained (ie, whole body data are not collected). Quantifications of femoral neck bone mineral density are the reference standard for diagnosing osteoporosis and for projecting future risk of hip fracture. 45 Obtaining a whole body DXA for body composition assessment requires additional scanning by the radiology technician and may have increased costs. However, whole body analyses provide essential information on total and regional adiposity, as well as quantification of LM for the classification of sarcopenia. 46 Newer DXA software is now available to calculate a more comprehensive definition of sarcopenia, taking into account measures of strength and LM. 47 Although the use of DXA for whole body composition assessment is relatively easy and poses minimal participant burden, having access to this machine and appropriately trained personnel further limits its use in select patient populations.
Future Directions
Traditionally, DXA has been considered the "gold standard" assessment technique to evaluate bone health. Despite its use since the 1980s and its demonstrated validity in healthy populations, its use to assess body composition across a breadth of disease entities remains relatively 
Question 2: Is US a valid method of assessing body composition in various clinical populations?
Recommendation No recommendation can be made at this time to support the use of US in the clinical setting for body composition assessment. No data exist to support its validity in adult patient populations.
Quality of the Evidence: Very Low GRADE Recommendation: Weak
Rationale
Seven studies utilizing US and a superior comparator method met the inclusion criteria for initial review and DAF completion. Studies included assessment of both adipose tissue and skeletal muscle. No studies included sensitivity or specificity analyses, and 2 included Bland-Altman analysis to compare measurements between techniques. Correlation analysis was included in all studies (see Table 5 for details regarding these studies). Patient populations included those with severe traumatic brain injury, 49 spinal cord injury, 50 COPD, 51, 52 obesity with metabolic syndrome/metabolic abnormalities, 53, 54 and patients with severe obesity postbariatric surgery. 55 Three studies used DXA to validate US measures, 49-51 3 used CT imaging, 52,54,55 and 1 used MRI. 53 The studies by Chappel et al, 49 Menon et al, 51 and Seymour et al 52 Comments US uses high-frequency sound waves to capture live images and soft tissue structures. For a thorough review of this methodology, please refer to Heymsfield et al. 2 US is a promising low-cost, low-risk, noninvasive, portable technique with wide applications in the clinical setting. It has been used to assess body composition, with most studies focusing on visceral and subcutaneous adiposity, 56 although it has been increasingly used for the assessment of SMM. An advantage of US for skeletal muscle assessment includes the quantification of muscle quantity and "quality" through different parameters (ie, muscle thickness, cross-sectional area, and echogenicity). Hydration status, reliability, and accuracy were previously considered inherent disadvantages of the method. However, these no longer pose as absolute contraindications, since several investigators have demonstrated that edema does not significantly influence body composition findings [57] [58] [59] and that adequate training results in excellent intraobserver and interobserver agreement. 60, 61 Currently, the major setback for its universal use is the lack of standardized measurement protocols, including which parameters to analyze, since data obtained from US measurements seem very informative yet are difficult to interpret and compare. Furthermore, there is no evidence yet to guide the alteration of nutrition provision based on US findings.
Future Directions
Within healthy, nonminority, free-living populations (ie, noninstitutionalized), US is a highly portable technique that can accurately measure VAT if completed by experienced, trained technicians. In patients with critical illness, US has the potential to be 1 of the best available methods for body composition evaluation, as the use of other techniques is largely infeasible in these patients.
The number of studies using US in clinical populations remains limited by several factors. First, most of the studies included in this review examined a single muscle. The utility and relevance of extrapolating single muscles to reflect overall nutrition status has yet to be determined. Further research efforts should evaluate whether the measurement of a single muscle or if select muscle groups can be used for clinical assessment, as measuring several anatomical sites is time consuming and limits widespread clinical use of this technique. In addition, since muscle atrophy can be disproportionate, 62 previous investigators have demonstrated the importance of investigating both upper and lower body muscle groups when evaluating longitudinal changes in body composition. 63 Second, US measurements often report muscle and/or adipose tissue as thickness (mm) or cross-sectional area (mm 2 ), whereas DXA data are presented as whole body mass (kg) and CT data may be reported as muscle cross-sectional area (cm 2 ). Furthermore, DXA and CT data can be indexed to height (kg/m 2 or cm/m 2 , respectively). Thus, it can be difficult to directly compare or interpret these data across devices. Methods to unify data reporting or interpretation are needed. Finally, the use of US in clinical settings would be significantly enhanced by establishment of measurement protocols for US muscle evaluation, including the handling of obtained parameters and their adequate interpretation.
Question 3: Is BIA a valid method of assessing body composition in various clinical populations?
Recommendation
No recommendations can be made regarding the validity of using BIA in clinical populations. Because of the proprietary nature of manufacture-specific BIA regression models to acquire body composition data, it is not possible to compare studies using different BIA devices. Furthermore, because of the variability of body compartments estimated within studies and the limited number of studies using the same device, it was not possible to merge data by manufacturer to support summary statistics.
Quality of the Evidence: Low GRADE Recommendation: Weak
Rationale
Twenty-nine studies using BIA and a superior comparator method were considered initially eligible for this review, and data were extracted using DAFs. However, BIA differs from the other methods (DXA and US) because it does not directly measure any specific body compartment. Rather, it provides estimates by using equations/algorithms populated by resistance, reactance, and impedance output from the BIA device combined with other parameters, including weight, height, sex, and age. Additionally, unlike other body composition techniques, BIA can be performed using a single frequency BIA (SF-BIA), multifrequency BIA (MF-BIA), or bioimpedance spectroscopy (BIS), all of which are produced from several different manufacturers. Each device works with a specific inbuilt algorithm to estimate body composition compartments.
To examine validity, device equations/algorithms would be tested against more precise body composition reference methods or use equations that were previously validated in a healthy population possessing similar characteristics to the clinical population under evaluation (eg, healthy Swiss men vs Swiss men with HIV). For this reason, 6 studies were further excluded, as (1) equations were used as the comparator method to validate body composition estimates using different target populations or (2) intraclass correlations and/or Bland-Altman statistics were used to show agreement. [64] [65] [66] [67] [68] [69] Only studies that compared the manufacturer's equation/algorithm against a superior method for body composition assessment (ie, DXA, CT, or MRI), studies that applied equations developed for the target population, or studies that provided correlation coefficients were considered in this review. Table 6 details the final 23 studies: 17 using MF-BIA or BIS devices, 70-86 5 using SF-BIA devices, 87-91 and 1 using MF-BIA and SF-BIA in the same study. 92 Most of the MF-BIA studies (13 of 16 MF-BIA) and all of the SF-BIA studies estimated FM and fat-free mass (FFM) either in kilograms or as a percentage of total body weight. Other compartments were estimated by using MF-BIA: total or segmental SMM 78, 82 or SMM index (SMI), 76 total or segmental LM, 74, 75 and total total fat area, intra-abdominal fat area, or subcutaneous fat area. 83, 84 Table 6 provides essential details for studies using BIA.
The majority of BIA studies included outpatients and reflects several clinical conditions, specifically hematologic; 70 end-stage chronic kidney disease (CKD) 73 ; end-stage CKD receiving hemodialysis 74, 78, 82, 92 ; CKD receiving peritoneal dialysis 75 or nondialyzed CKD 89 ; rheumatic disease 76 ; HIV 77, 87, 90 ; COPD 79, 88 ; pre-liver or post-liver, lung, or heart transplantation 80 ; cardiac surgery 81 ; obesity with metabolic syndrome 84 ; cystic fibrosis 91 ; and nonalcoholic fatty liver disease. 67 Only 4 studies were performed in hospitalized patients, encompassing several clinical conditions (congestive heart failure, coronary heart disease, essential hypertension, atherosclerosis, kidney disease, chronic renal failure, gastrointestinal diseases, type II diabetes, morbid obesity, osteoporosis, cancer, chronic polyarthritis, and anorexia nervosa), 72 obesity with caloric restriction 83 or bariatric surgery candidates, 86 and patients following stroke or transient ischemic attack. 85 Due to the proprietary nature of manufacturer-specific BIA regression models to estimate body composition, it was not possible to compare studies using different BIA devices (eg, Inbody 720 vs Quadscan 4000). Furthermore, within studies using the same device (eg, all studies using the Inbody 720), it was not possible to conflate these data due to the variability of body compartments estimated.
Comments
BIA measures the opposition of an electrical current through body tissues (ie, impedance), which can then be used to estimate total body water and body composition. For a detailed review of this methodology, please refer to Heymsfield et al. 2 BIA is a practical, portable, noninvasive tool that poses minimal risks and low costs relative to the other body composition assessment methods. These characteristics allow its use in any setting, such as epidemiological and clinical studies, and render BIA an ideal assessment technique for follow-up studies, in which repeated measurements are necessary and easily obtained. At the present time, SF-BIA or MF-BIA devices can measure total body or segmental impedance or its components (resistance and reactance). All BIA devices, except BIA spectroscopy, use equations/algorithms that have been developed based or validated against other body composition reference methods. BIA equations are highly specific for the device and for the population for which they were developed. Therefore, BIA validation studies only have an external validity when the same combination of device/equation/population is used. 80 An acceptable mean level accuracy for BIA assessments has been established in healthy, nonobese participants. 93 In the clinical setting, good correlations between BIA-assessed body compartments were found when compared with gold standard techniques; however, the large limits of agreement confirmed the need for cautious interpretation for individual patients. 94 Because BIA precision and accuracy are highly influenced by fever, certain medications, and fluid and electrolyte disturbances, these common clinical occurrences may nonuniformly alter BIA findings among clinical populations.
Future Directions
BIA demonstrates good correlations with superior reference methods in several outpatient populations; however, very few BIA validation studies have been performed in hospitalized patients. Given its superiority to other body composition methods with regard to portability, cost, and risk, the lack of validation studies may reflect limited access to the necessary reference methods, such as DXA or CT, for validation. This merits exploration in future research efforts. Additionally, an emerging area of research is derived from the fact that BIA can accurately estimate phase angle (PA), now considered a surrogate of not only LM 95 but also of LM quality. 96 Different from BIA body composition estimations, PA is directly obtained from resistance and reactance; raw BIA parameters are available from any single frequency BIA device. Intervention studies, which include resistance training, show improvements in PA, which then correlate with gains in LM. 97 Future studies comparing PA with skeletal muscle estimation from CT images or other gold standard techniques may show its relevance and wideranging applications for body composition assessment in clinical settings.
Summary
Initially and ideally, the task force wanted to compare studies by target population and within body composition assessment methodology (eg, patients with hepatic disease analyzed using DXA). Additionally, the goal was to further analyze studies comparing investigations that included healthy volunteers and a clinical population within body composition assessment methodology (eg, patients with hepatic disease vs healthy controls analyzed using DXA). It was also speculated that the analyses would include studies by exact hardware (eg, patients with hepatic disease vs healthy controls analyzed using a specific DXA machine). When the searches failed to yield any studies that met these criteria to apply and converge data for evaluation using GRADE, the task force was charged with establishing the diagnostic accuracy of these methods in nonhealthy populations. The PRISMA recommendations 5 are summarized and include 22 items. Only the first 13 items in the checklist were available in the studies included in this systematic review. Thus, for the final analyses, correlation coefficients were combined based on a specific body compartment and all disease entities and hardware grouped together (eg, CT VAT vs DXA abdominal fat, any disease state, any manufacturer). Although this was not the original intended approach and the results do not highlight the usefulness of these techniques in certain clinical populations, this review and evaluation provides a snapshot of where the science is today in the clinical arena. This work lays an important foundation for establishing guidelines in the future and affords the opportunity to make recommendations for advancement.
To comprehensively evaluate the utility of these techniques in specific patient populations, several gaps require attention going forward. First, the lack of standardized body composition terminology across studies is problematic, regardless of technique. A multitude of names are used by investigators for similar, although distinct, body compartments. As noted in Table 1 , lean soft tissue is often referred to as skeletal muscle, muscle tissue, or FFM. However, the term FFM technically includes lean soft tissue plus the bone mineral compartment, whereas skeletal muscle does not. Similar issues arose involving studies investigating abdominal obesity, as the terms VAT, intraabdominal fat, trunk fat, visceral fat, or visceral FM were used by numerous investigators. Unifying and applying appropriate body composition terminology is an important fundamental step to avoid confusion, to improve accuracy, and to allow more precise comparisons across studies. For example, CT analyses can differentiate 2 types of subcutaneous adipose tissue-superficial vs deep-and studies support differential disease risks associated with these distinct tissues. 98, 99 Using the term intraabdominal fat or trunk fat would not permit this important differentiation. Thus, as imaging becomes more sophisticated, using the appropriate language to discriminate and distinguish these compartments is vital to advancing general knowledge on the potential relationships between specific body compartments and health outcomes. Researchers, clinicians, and editors should ensure that future work apply and adhere to a similar human body composition vernacular.
Second, there is a considerable need to develop cutpoints to categorize characteristics of interest in body composition, such as "malnourished," "inadequate or optimal lean mass," or "inadequate, adequate, or excess fat mass." Without these cut-points to then classify or categorize patients, clinicians are greatly limited in their abilities to utilize measures of body composition in the context of patient care. For example, the term "sarcopenia" is often used synonymously with the term "malnourished." Considering that the root cause of these 2 conditions may be inherently different, using these terms interchangeably is clinically inaccurate. Furthermore, once cut-points are established, sensitivity and specificity measurements (thus, true and/or false positives and true and/or false negative classifications) with 95% confidence intervals can be calculated. For now, body composition data must be evaluated as a continuous variable, and only agreement estimates can be used to appraise the overall quality of the studies used.
Third, basic principles of study design and inclusion require greater focus. Studies with sufficient sample size and statistical power are needed. Only a few studies (DXA and BIA) included in this systematic review possessed study populations larger than 100 participants. To achieve adequate numbers, studies of longer duration are warranted to ensure adequate accrual or investigations with >1 study site may be required. Furthermore, to make adequate comparisons across techniques, the inclusion of "healthy controls" is critical. This review was greatly limited by this basic principle and by the lack of inclusion of minority populations. Several studies have documented differences in body composition by race/ethnicity for predicting disease risk. [100] [101] [102] Therefore, consideration should be given to potential sources of relevant comparative data in the public domain (eg, NHANES) or for collaborating with investigators who have published in diverse, healthy populations. Equally important are concerns related to statistical analyses and data interpretation. One of the challenges in working with body composition data is the belief that these tissue compartments behave independently. That is, as LM changes, FM stays the same (or vice versa). For interventions focused on diet and physical activity, changes in both compartments would be anticipated. Therefore, in order to examine clinically relevant outcomes, it is important to appreciate and understand the interplay between these metabolically and anatomically distinct compartments. Moreover, linking changes in lean and/or FM with serum biomarkers of disease (eg, blood lipids, insulin, leptin, adiponectin, C-reactive protein) may require sophisticated statistical modeling to account for simultaneous, bidirectional changes.
In conclusion, the task force acknowledges the paucity of high-level evidence for body composition assessment in clinical populations, especially those with the same underlying diagnosis. Although the systematic search strategy followed by meticulous data abstraction allowed us to capture the majority of relevant studies, it is important to note that a portion of the data abstraction was conducted in studies that were not necessarily driven by validity but possessed other study purposes. Thus, the task force may have inadvertently missed studies that could have provided evaluable data points. Also, the analyses were limited to aggregating simple agreement statistics across studies, and several authors did not report such findings. Bland-Altman and concordance correlation coefficients (which reflect precision and accuracy) would have been ideal to assess agreement between body composition methodologies; however, the availability of these statistics would have restricted this review to only a handful of investigations. Regardless of these limitations and potential oversights, we have summarized key areas for future investigations and future guideline development. As our interest in body composition continues to gain substantial interest, a more comprehensive evaluation of the validity of these techniques in various clinical populations is warranted, especially those that reflect the ethnic and racial diversity in our hospitals and clinics.
